Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regenerx Biopharmaceuticals, a biopharmaceutical company focused on the discovery and development of molecules to promote tissue and organ repair, has announced that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis.
Subscribe to our email newsletter
According to the company, RGN-457 is based on thymosin beta 4 peptide formulated as an inhaled therapeutic agent to address the cystic fibrosis patient population.
JJ Finkelstein, RegeneRx’s president and CEO, said: “We have completed a substantial amount of preclinical work necessary for an investigational new drug application, in addition to existing toxicology and pharmacokinetic data from our current clinical programs.
“We believe RGN-457 could be developed relatively quickly with appropriate resources, thus, our interest is in identifying a strong strategic partner to work with us on this important product opportunity.”